Role of integrated cancer nanomedicine in overcoming drug resistance

Advanced Drug Delivery Reviews

Volumn 65, Issue 13-14, 2013, Pages 1784-1802

  Iyer, Arun K ^a   Singh, Amit ^a   Ganta, Srinivas ^b   Amiji, Mansoor M ^a  

^a NORTHEASTERN UNIVERSITY   (United States)

^b Nemucore Medical Innovations Inc   (United States)

Author keywords

Cancer stem cells; Imaging; Multifunctional nanosystems; Targeted delivery; Tumor multidrug resistance

Indexed keywords

CANCER STEM CELLS; DRUG RESISTANCE; MULTI-FUNCTIONAL NANOPARTICLES; MULTIDRUG RESISTANCE; NANOPARTICLE SYSTEMS; STIMULI-RESPONSIVE; TARGETED DELIVERY; TARGETING LIGANDS;

CHEMOTHERAPY; IMAGING TECHNIQUES; NANOPARTICLES; NANOSYSTEMS; ONCOLOGY; STEM CELLS; TUMORS;

DISEASES;

ANTHRACYCLINE; ANTINEOPLASTIC AGENT; APTAMER; BEVACIZUMAB; CETUXIMAB; CURCUMIN; DENDRIMER; DOXORUBICIN; GEMCITABINE; HYALURONIC ACID; LIPOSOME; MACROGOL; NANOPARTICLE; PACLITAXEL; PANITUMUMAB; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PLATINUM COMPLEX; POLYGLACTIN; RETINOIC ACID; SALINOMYCIN; SHORT HAIRPIN RNA; SMALL INTERFERING RNA; TAXANE DERIVATIVE; TEGAFUR; TRICHOSTATIN A; UNINDEXED DRUG; VERAPAMIL; VINBLASTINE; VINCA ALKALOID; VORINOSTAT;

ACUTE GRANULOCYTIC LEUKEMIA; ANTINEOPLASTIC ACTIVITY; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER STEM CELL; CANCER THERAPY; CELL HYPOXIA; COLON CANCER; COLORECTAL CANCER; DRUG BIOAVAILABILITY; DRUG CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG POTENTIATION; DRUG RESISTANCE; DRUG SELECTIVITY; DRUG SENSITIZATION; DRUG TARGETING; GENE THERAPY; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; LIVER CELL CARCINOMA; LUNG CANCER; LUNG NON SMALL CELL CANCER; METASTASIS; MICELLE; MOLECULARLY TARGETED THERAPY; MONOTHERAPY; MULTIDRUG RESISTANCE; NANOMEDICINE; NONHUMAN; OVARY CANCER; PANCREAS CANCER; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; RNA INTERFERENCE; SOLID TUMOR; TUMOR MICROENVIRONMENT;

1,2-DISTEAROYL-SN-GLYCERO 3-PHOSPHOCHOLINE; AAC; ACRYLIC ACID; ACUTE MYELOID LEUKEMIA; AML; ARGININE-GLYCINE-ASPARTIC ACID; BCP; BK; BLOCK COPOLYMER; BRADYKININ; CANCER STEM CELLS; CD; CETYLTRIMETHYLAMMONIUM BROMIDE; CHOL; CHOLESTEROL; CSC; CTAB; CYCLODEXTRIN; DDS; DELTA-LIKE 4 LIGAND; DEX; DEXAMETHASONE; DIOLEOYLPHOSPHATIDYLGLYCEROL; DIPALMITOYLPHOSPHATIDYLCHOLINE; DLL4; DMAEMA; DOPG; DOX; DOXORUBICIN; DPPC; DRUG DELIVERY SYSTEM; DSPC; ECM; EGFR; EMT; ENHANCED PERMEABILITY AND RETENTION; EOEOVE; EPCAM; EPIDERMAL GROWTH FACTOR RECEPTOR; EPITHELIAL CELL ADHESION MOLECULE; EPITHELIAL-MESENCHYMAL TRANSITION; EPR; EXTRACELLULAR MATRIX; GAMMA-INTERFERON-INDUCIBLE LYSOSOMAL THIOL REDUCTASE; GILT; HDAC; HFMF; HIFU; HIGH INTENSITY FOCUSED ULTRASOUND; HIGH-FREQUENCY MAGNETIC FIELD; HISTONE DEACETYLASE; HPMA; IARC; IMAGING; INFRA-RED; INTERNATIONAL AGENCY FOR RESEARCH ON CANCER; INTERPENETRATING NETWORKS; IPNS; LCST; LOW THERMOSENSITIVE LIPOSOMES; LOWER CRITICAL SOLUTION TEMPERATURE; LTSL; MA; MAAC; MAGNETIC RESONANCE IMAGING; MALEIC ANHYDRIDE (MA); MATRIX METALLOPROTEINASE; MDR; MESOPOROUS SILICA NANOPARTICLES; METHACRYLIC ACID; MMPS; MONONUCLEAR PHAGOCYTIC SYSTEM; MPS; MRI; MSNP; MSNS; MULTI-DRUG RESISTANCE; MULTIFUNCTIONAL NANOSYSTEMS; N,N-DIMETHYLAMINOETHYL METHACRYLATE; NERVE GROWTH FACTOR; NGF; NIR; NITRIC OXIDE; NO; NON-SMALL CELL LUNG CANCER; NON-THERMOSENSITIVE LIPOSOMES; NSCLC; NTSL; P-GLYCOPROTEIN; P-GP; PAA; PAM; PBAE; PCL; PDDA; PDEAAM; PDMAEMA; PEG; PEI; PEO; PGA; PGS; PHEA; PLGA; PNIPAAM; POLY(AMIDOAMINE); POLY(CAPROLACTONE); POLY(D,L-LACTIDE-CO-GLYCOLIDE); POLY(DIMETHYLDIALLYLAMMONIUM CHLORIDE); POLY(ETHYLENE GLYCOL); POLY(ETHYLENE OXIDE); POLY(GLUTAMIC ACID); POLY(N,N-DIETHYLACRYLAMIDE); POLY(N-(2-HYDROXYPROPYL)METHACRYLAMIDE); POLY(N-ISOPROPYL ACRYLAMIDE); POLY(N-VINLYCAPROLACTAM); POLY(TRIMETHYLENE CARBONATE); POLY(Β-AMINO ESTER); POLYACRYLAMIDE; POLYETHYLENEIMINE; POLY[2-(2-ETHOXY)ETHOXYETHYL VINYL ETHER]; POLY[2-(DIMETHYLAMINO)ETHYL METHACRYLATE]; PROSTAGLANDINS; PROSTATE-SPECIFIC MEMBRANE ANTIGEN; PSMA; PTMC; PVCL; RGD; RNA INTERFERENCE; RNAI; SCLC; SHORT HAIRPIN RNA; SHRNA; SIDE POPULATION; SIRNA; SMALL CELL LUNG CANCER; SMALL INTERFERING RNA; SP; SPIONS; SUPERPARAMAGNETIC IRON OXIDE NANOPARTICLES; TARGETED DELIVERY; TEGAFUR; TF; THERMOSENSITIVE LIPOSOMES; TTSL; TUMOR MULTIDRUG RESISTANCE; UCNPS; UCST; ULTRASOUND; UPCONVERTING NANOPARTICLES; UPPER CRITICAL SOLUTION TEMPERATURE; US; VASCULAR ENDOTHELIAL GROWTH FACTOR; VASCULAR PERMEABILITY FACTOR; VEGF; VPF; Α,Β-POLY(N-2-HYDROXYETHYL)-D,L-ASPARTAMIDE;

ANIMALS; ANTINEOPLASTIC AGENTS; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; DRUG RESISTANCE, NEOPLASM; HUMANS; MOLECULAR TARGETED THERAPY; NANOMEDICINE; NANOPARTICLES; NEOPLASMS;

EID: 84888201303     PISSN: 0169409X     EISSN: 18728294     Source Type: Journal    
DOI: 10.1016/j.addr.2013.07.012     Document Type: Review

References (242)

1. Allen T.M., Cullis P.R. Drug delivery systems: entering the mainstream. Science 2004, 303:1818-1822.
2. Tsuruo T., Naito M., Tomida A., Fujita N., Mashima T., Sakamoto H., Haga N. Molecular targeting therapy of cancer: drug resistance, apoptosis and survival signal. Cancer Sci. 2003, 94:15-21.
3. Donnenberg V.S., Donnenberg A.D. Multiple drug resistance in cancer revisited: the cancer stem cell hypothesis. J. Clin. Pharmacol. 2005, 45:872-877.
4. Singh A., Settleman J. EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer. Oncogene 2010, 29:4741-4751.
5. Witta S.E., Jotte R.M., Konduri K., Neubauer M.A., Spira A.I., Ruxer R.L., Varella-Garcia M., Bunn P.A., Hirsch F.R. Randomized phase II trial of erlotinib with and without entinostat in patients with advanced non-small-cell lung cancer who progressed on prior chemotherapy. J. Clin. Oncol. 2012, 30:2248-2255.
6. Tang D.G. Understanding cancer stem cell heterogeneity and plasticity. Cell Res. 2012, 22:457-472.
7. Vicente-Duenas C., Gutierrez de Diego J., Rodriguez F.D., Jimenez R., Cobaleda C. The role of cellular plasticity in cancer development. Curr. Med. Chem. 2009, 16:3676-3685.
8. Lipkin G. Plasticity of the cancer cell: implications for epigenetic control of melanoma and other malignancies. J. Investig. Dermatol. 2008, 128:2152-2155.
9. Leder K., Holland E.C., Michor F. The therapeutic implications of plasticity of the cancer stem cell phenotype. PLoS One 2010, 5:e14366.
10. Frank N.Y., Schatton T., Frank M.H. The therapeutic promise of the cancer stem cell concept. J. Clin. Investig. 2010, 120:41-50.
11. Mihic-Probst D., Ikenberg K., Tinguely M., Schraml P., Behnke S., Seifert B., Civenni G., Sommer L., Moch H., Dummer R. Tumor cell plasticity and angiogenesis in human melanomas. PLoS One 2012, 7:e33571.
12. Grunert S., Jechlinger M., Beug H. Diverse cellular and molecular mechanisms contribute to epithelial plasticity and metastasis. Nat. Rev. Mol. Cell Biol. 2003, 4:657-665.
13. Thiery J.P. Epithelial-mesenchymal transitions in tumour progression. Nat. Rev. Cancer 2002, 2:442-454.
14. Saunders N.A., Simpson F., Thompson E.W., Hill M.M., Endo-Munoz L., Leggatt G., Minchin R.F., Guminski A. Role of intratumoural heterogeneity in cancer drug resistance: molecular and clinical perspectives. EMBO Mol. Med. 2012, 4:675-684.
15. Gottesman M.M., Fojo T., Bates S.E. Multidrug resistance in cancer: role of ATP-dependent transporters. Nat. Rev. Cancer 2002, 2:48-58.
16. Gupta P.B., Chaffer C.L., Weinberg R.A. Cancer stem cells: mirage or reality?. Nat. Med. 2009, 15:1010-1012.
17. Visvader J.E., Lindeman G.J. Cancer stem cells in solid tumours: accumulating evidence and unresolved questions. Nat. Rev. Cancer 2008, 8:755-768.
18. Vinogradov S., Wei X. Cancer stem cells and drug resistance: the potential of nanomedicine. Nanomedicine (London, England) 2012, 7:597-615.
19. Dick J.E. Looking ahead in cancer stem cell research. Nat. Biotechnol. 2009, 27:44-46.
20. Bonnet D., Dick J.E. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat. Med. 1997, 3:730-737.
21. Adams J.M., Strasser A. Is tumor growth sustained by rare cancer stem cells or dominant clones?. Cancer Res. 2008, 68:4018-4021.
22. Al-Hajj M., Wicha M.S., Benito-Hernandez A., Morrison S.J., Clarke M.F. Prospective identification of tumorigenic breast cancer cells. Proc. Natl. Acad. Sci. U.S.A. 2003, 100:3983-3988.
23. Ricci-Vitiani L., Lombardi D.G., Pilozzi E., Biffoni M., Todaro M., Peschle C., De Maria R. Identification and expansion of human colon-cancer-initiating cells. Nature 2007, 445:111-115.
24. Hope K.J., Jin L., Dick J.E. Acute myeloid leukemia originates from a hierarchy of leukemic stem cell classes that differ in self-renewal capacity. Nat. Immunol. 2004, 5:738-743.
25. Li C., Heidt D.G., Dalerba P., Burant C.F., Zhang L., Adsay V., Wicha M., Clarke M.F., Simeone D.M. Identification of pancreatic cancer stem cells. Cancer Res. 2007, 67:1030-1037.
26. Wu C., Wei Q., Utomo V., Nadesan P., Whetstone H., Kandel R., Wunder J.S., Alman B.A. Side population cells isolated from mesenchymal neoplasms have tumor initiating potential. Cancer Res. 2007, 67:8216-8222.
27. Prince M.E., Sivanandan R., Kaczorowski A., Wolf G.T., Kaplan M.J., Dalerba P., Weissman I.L., Clarke M.F., Ailles L.E. Identification of a subpopulation of cells with cancer stem cell properties in head and neck squamous cell carcinoma. Proc. Natl. Acad. Sci. U.S.A. 2007, 104:973-978.
28. Mani S.A., Yang J., Brooks M., Schwaninger G., Zhou A., Miura N., Kutok J.L., Hartwell K., Richardson A.L., Weinberg R.A. Mesenchyme Forkhead 1 (FOXC2) plays a key role in metastasis and is associated with aggressive basal-like breast cancers. Proc. Natl. Acad. Sci. U.S.A. 2007, 104:10069-10074.
29. Ostman A. The tumor microenvironment controls drug sensitivity. Nat. Med. 2012, 18:1332-1334.
30. Tredan O., Galmarini C.M., Patel K., Tannock I.F. Drug resistance and the solid tumor microenvironment. J. Natl. Cancer Inst. 2007, 99:1441-1454.
31. Jabr-Milane L.S., van Vlerken L.E., Yadav S., Amiji M.M. Multi-functional nanocarriers to overcome tumor drug resistance. Cancer Treat. Rev. 2008, 34:592-602.
32. Comerford K.M., Wallace T.J., Karhausen J., Louis N.A., Montalto M.C., Colgan S.P. Hypoxia-inducible factor-1-dependent regulation of the multidrug resistance (MDR1) gene. Cancer Res. 2002, 62:3387-3394.
33. Harris A.L. Hypoxia-a key regulatory factor in tumour growth. Nat. Rev. Cancer 2002, 2:38-47.
34. Milane L., Duan Z., Amiji M. Role of hypoxia and glycolysis in the development of multi-drug resistance in human tumor cells and the establishment of an orthotopic multi-drug resistant tumor model in nude mice using hypoxic pre-conditioning. Cancer Cell Int. 2011, 11:3.
35. Milane L., Ganesh S., Shah S., Duan Z.F., Amiji M. Multi-modal strategies for overcoming tumor drug resistance: hypoxia, the Warburg effect, stem cells, and multifunctional nanotechnology. J. Control. Release 2011, 155:237-247.
36. Guppy M. The hypoxic core: a possible answer to the cancer paradox. Biochem. Biophys. Res. Commun. 2002, 299:676-680.
37. Gillet J.P., Efferth T., Remacle J. Chemotherapy-induced resistance by ATP-binding cassette transporter genes. Biochim. Biophys. Acta 2007, 1775:237-262.
38. Allikmets R., Gerrard B., Hutchinson A., Dean M. Characterization of the human ABC superfamily: isolation and mapping of 21 new genes using the expressed sequence tags database. Hum. Mol. Genet. 1996, 5:1649-1655.
39. Fukuda Y., Schuetz J.D. ABC transporters and their role in nucleoside and nucleotide drug resistance. Biochem. Pharmacol. 2012, 83:1073-1083.
40. Nobili S., Landini I., Giglioni B., Mini E. Pharmacological strategies for overcoming multidrug resistance. Curr. Drug Targets 2006, 7:861-879.
41. Ding L., Ley T.J., Larson D.E., Miller C.A., Koboldt D.C., Welch J.S., Ritchey J.K., Young M.A., Lamprecht T., McLellan M.D., McMichael J.F., Wallis J.W., Lu C., Shen D., Harris C.C., Dooling D.J., Fulton R.S., Fulton L.L., Chen K., Schmidt H., Kalicki-Veizer J., Magrini V.J., Cook L., McGrath S.D., Vickery T.L., Wendl M.C., Heath S., Watson M.A., Link D.C., Tomasson M.H., Shannon W.D., Payton J.E., Kulkarni S., Westervelt P., Walter M.J., Graubert T.A., Mardis E.R., Wilson R.K., DiPersio J.F. Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencing. Nature 2012, 481:506-510.
42. Navin N., Kendall J., Troge J., Andrews P., Rodgers L., McIndoo J., Cook K., Stepansky A., Levy D., Esposito D., Muthuswamy L., Krasnitz A., McCombie W.R., Hicks J., Wigler M. Tumour evolution inferred by single-cell sequencing. Nature 2011, 472:90-94.
43. Shervington A., Lu C. Expression of multidrug resistance genes in normal and cancer stem cells. Cancer Invest. 2008, 26:535-542.
44. Steg A.D., Bevis K.S., Katre A.A., Ziebarth A., Dobbin Z.C., Alvarez R.D., Zhang K., Conner M., Landen C.N. Stem cell pathways contribute to clinical chemoresistance in ovarian cancer. Clin. Cancer Res. 2012, 18:869-881.
45. Jin F., Zhao L., Guo Y.J., Zhao W.J., Zhang H., Wang H.T., Shao T., Zhang S.L., Wei Y.J., Feng J., Jiang X.B., Zhao H.Y. Influence of Etoposide on anti-apoptotic and multidrug resistance-associated protein genes in CD133 positive U251 glioblastoma stem-like cells. Brain Res. 2010, 1336:103-111.
46. Hu C., Li H., Li J., Zhu Z., Yin S., Hao X., Yao M., Zheng S., Gu J. Analysis of ABCG2 expression and side population identifies intrinsic drug efflux in the HCC cell line MHCC-97L and its modulation by Akt signaling. Carcinogenesis 2008, 29:2289-2297.
47. Hortobagyi G.N. Anthracyclines in the treatment of cancer. An overview. Drugs 1997, 54(Suppl. 4):1-7.
48. Pai S.I., Lin Y.Y., Macaes B., Meneshian A., Hung C.F., Wu T.C. Prospects of RNA interference therapy for cancer. Gene Ther. 2006, 13:464-477.
49. Aagaard L., Rossi J.J. RNAi therapeutics: principles, prospects and challenges. Adv. Drug Deliv. Rev. 2007, 59:75-86.
50. Whitehead K.A., Langer R., Anderson D.G. Knocking down barriers: advances in siRNA delivery. Nat. Rev. Drug Discov. 2009, 8:129-138.
51. Zhang L., Gu F.X., Chan J.M., Wang A.Z., Langer R.S., Farokhzad O.C. Nanoparticles in medicine: therapeutic applications and developments. Clin. Pharmacol. Ther. 2008, 83:761-769.
52. Farokhzad O.C., Langer R. Impact of nanotechnology on drug delivery. ACS Nano 2009, 3:16-20.
53. Matsumura Y., Maeda H. A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res. 1986, 46:6387-6392.
54. Folkman J. What is the evidence that tumors are angiogenesis dependent?. J. Natl. Cancer Inst. 1990, 82:4-6.
55. Greish K., Fang J., Inutsuka T., Nagamitsu A., Maeda H. Macromolecular therapeutics: advantages and prospects with special emphasis on solid tumour targeting. Clin. Pharmacokinet. 2003, 42:1089-1105.
56. Maeda H., Sawa T., Konno T. Mechanism of tumor-targeted delivery of macromolecular drugs, including the EPR effect in solid tumor and clinical overview of the prototype polymeric drug SMANCS. J. Control. Release 2001, 74:47-61.
57. Dreher M.R., Liu W., Michelich C.R., Dewhirst M.W., Yuan F., Chilkoti A. Tumor vascular permeability, accumulation, and penetration of macromolecular drug carriers. J. Natl. Cancer Inst. 2006, 98:335-344.
58. Yuan F., Dellian M., Fukumura D., Leunig M., Berk D.A., Torchilin V.P., Jain R.K. Vascular permeability in a human tumor xenograft: molecular size dependence and cutoff size. Cancer Res. 1995, 55:3752-3756.
59. Iyer A.K., Khaled G., Fang J., Maeda H. Exploiting the enhanced permeability and retention effect for tumor targeting. Drug Discov. Today 2006, 11:812-818.
60. Maeda H., Wu J., Sawa T., Matsumura Y., Hori K. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J. Control. Release 2000, 65:271-284.
61. Maeda H. The enhanced permeability and retention (EPR) effect in tumor vasculature: the key role of tumor-selective macromolecular drug targeting. Adv. Enzym. Regul. 2001, 41:189-207.
62. Li S.-D., Huang L. Stealth nanoparticles: high density but sheddable PEG is a key for tumor targeting. J. Control. Release 2010, 145:178-181.
63. Owens D.E., Peppas N.A. Opsonization, biodistribution, and pharmacokinetics of polymeric nanoparticles. Int. J. Pharm. 2006, 307:93-102.
64. Veronese F.M., Pasut G. PEGylation, successful approach to drug delivery. Drug Discov. Today 2005, 10:1451-1458.
65. Torchilin V.P. Recent advances with liposomes as pharmaceutical carriers. Nat. Rev. Drug Discov. 2005, 4:145-160.
66. Dobrovolskaia M.A., McNeil S.E. Immunological properties of engineered nanomaterials. Nat. Nanotechnol. 2007, 2:469-478.
67. Torchilin V.P. Passive and active drug targeting: drug delivery to tumors as an example. Handb. Exp. Pharmacol. 2010, 3-53.
68. Sethuraman V.A., Bae Y.H. TAT peptide-based micelle system for potential active targeting of anti-cancer agents to acidic solid tumors. J. Control. Release 2007, 118:216-224.
69. Jabr-Milane L.S., van Vlerken L.E., Yadav S., Amiji M.M. Multi-functional nanocarriers to overcome tumor drug resistance. Cancer Treat. Rev. 2008, 34:592-602.
70. Magadala P., Amiji M. Epidermal growth factor receptor-targeted gelatin-based engineered nanocarriers for DNA delivery and transfection in human pancreatic cancer cells. AAPS J. 2008, 10:565-576.
71. Iyer A.K., He J., Amiji M.M. Image-guided nanosystems for targeted delivery in cancer therapy. Curr. Med. Chem. 2012, 19:3230-3240.
72. Marcucci F., Lefoulon F. Active targeting with particulate drug carriers in tumor therapy: fundamentals and recent progress. Drug Discov. Today 2004, 9:219-228.
73. Milane L., Duan Z., Amiji M. Development of EGFR-targeted polymer blend nanocarriers for combination paclitaxel/lonidamine delivery to treat multi-drug resistance in human breast and ovarian tumor cells. Mol. Pharm. 2011, 8:185-203.
74. Iftimia N., Iyer A.K., Hammer D.X., Lue N., Mujat M., Pitman M., Ferguson R.D., Amiji M. Fluorescence-guided optical coherence tomography imaging for colon cancer screening: a preliminary mouse study. Biomed. Opt. Express 2012, 3:178-191.
75. Sugahara K.N., Teesalu T., Karmali P.P., Kotamraju V.R., Agemy L., Greenwald D.R., Ruoslahti E. Coadministration of a tumor-penetrating peptide enhances the efficacy of cancer drugs. Science 2010, 328:1031-1035.
76. Hallahan D., Geng L., Qu S., Scarfone C., Giorgio T., Donnelly E., Gao X., Clanton J. Integrin-mediated targeting of drug delivery to irradiated tumor blood vessels. Cancer Cell 2003, 3:63-74.
77. Werner M.E., Karve S., Sukumar R., Cummings N.D., Copp J.A., Chen R.C., Zhang T., Wang A.Z. Folate-targeted nanoparticle delivery of chemo- and radiotherapeutics for the treatment of ovarian cancer peritoneal metastasis. Biomaterials 2011, 32:8548-8554.
78. Dassie J.P., Liu X.Y., Thomas G.S., Whitaker R.M., Thiel K.W., Stockdale K.R., Meyerholz D.K., McCaffrey A.P., McNamara J.O., Giangrande P.H. Systemic administration of optimized aptamer-siRNA chimeras promotes regression of PSMA-expressing tumors. Nat. Biotechnol. 2009, 27:839-849.
79. Chu T.C., Twu K.Y., Ellington A.D., Levy M. Aptamer mediated siRNA delivery. Nucleic Acids Res. 2006, 34:e73.
80. Ferrari M. Frontiers in cancer nanomedicine: directing mass transport through biological barriers. Trends Biotechnol. 2010, 28:181-188.
81. Sinha R., Kim G.J., Nie S., Shin D.M. Nanotechnology in cancer therapeutics: bioconjugated nanoparticles for drug delivery. Mol. Cancer Ther. 2006, 5:1909-1917.
82. Panyam J., Labhasetwar V. Biodegradable nanoparticles for drug and gene delivery to cells and tissue. Adv. Drug Deliv. Rev. 2003, 55:329-347.
83. Merisko-Liversidge E.M., Liversidge G.G. Drug nanoparticles: formulating poorly water-soluble compounds. Toxicol. Pathol. 2008, 36:43-48.
84. Devalapally H., Duan Z., Seiden M.V., Amiji M.M. Paclitaxel and ceramide co-administration in biodegradable polymeric nanoparticulate delivery system to overcome drug resistance in ovarian cancer. Int. J. Cancer 2007, 121:1830-1838.
85. Ganta S., Amiji M. Coadministration of Paclitaxel and curcumin in nanoemulsion formulations to overcome multidrug resistance in tumor cells. Mol. Pharm. 2009, 6:928-939.
86. Yoo J.W., Doshi N., Mitragotri S. Adaptive micro and nanoparticles: temporal control over carrier properties to facilitate drug delivery. Adv. Drug Deliv. Rev. 2011, 63:1247-1256.
87. Bhavsar M.D., Amiji M.M. Gastrointestinal distribution and in vivo gene transfection studies with nanoparticles-in-microsphere oral system (NiMOS). J. Control. Release 2007, 119:339-348.
88. Wang Y., Wang B., Qiao W., Yin T. A novel controlled release drug delivery system for multiple drugs based on electrospun nanofibers containing nanoparticles. J. Pharm. Sci. 2010, 99:4805-4811.
89. zur Muhlen A., Schwarz C., Mehnert W. Solid lipid nanoparticles (SLN) for controlled drug delivery-drug release and release mechanism. Eur. J. Pharm. Biopharm. 1998, 45:149-155.
90. Abeylath S.C., Ganta S., Iyer A.K., Amiji M. Combinatorial-designed multifunctional polymeric nanosystems for tumor-targeted therapeutic delivery. Acc. Chem. Res. 2011, 44:1009-1017.
91. Jabr-Milane L., van Vlerken L., Devalapally H., Shenoy D., Komareddy S., Bhavsar M., Amiji M. Multi-functional nanocarriers for targeted delivery of drugs and genes. J. Control. Release 2008, 130:121-128.
92. Boddapati S.V., D'Souza G.G., Erdogan S., Torchilin V.P., Weissig V. Organelle-targeted nanocarriers: specific delivery of liposomal ceramide to mitochondria enhances its cytotoxicity in vitro and in vivo. Nano Lett. 2008, 8:2559-2563.
93. Janib S.M., Moses A.S., MacKay J.A. Imaging and drug delivery using theranostic nanoparticles. Adv. Drug Deliv. Rev. 2010, 62:1052-1063.
94. Maugeri-Sacca M., Zeuner A., De Maria R. Therapeutic targeting of cancer stem cells. Front. Oncol. 2011, 1:10.
95. Hu C.M., Zhang L. Nanoparticle-based combination therapy toward overcoming drug resistance in cancer. Biochem. Pharmacol. 2012, 83:1104-1111.
96. Al-Lazikani B., Banerji U., Workman P. Combinatorial drug therapy for cancer in the post-genomic era. Nat. Biotechnol. 2012, 30:679-692.
97. Woodcock J., Griffin J.P., Behrman R.E. Development of novel combination therapies. N. Engl. J. Med. 2011, 364:985-987.
98. Chabner B.A., Roberts T.G. Timeline: chemotherapy and the war on cancer. Nat. Rev. Cancer 2005, 5:65-72.
99. Delbaldo C., Michiels S., Syz N., Soria J.C., Le Chevalier T., Pignon J.P. Benefits of adding a drug to a single-agent or a 2-agent chemotherapy regimen in advanced non-small-cell lung cancer: a meta-analysis. JAMA 2004, 292:470-484.
100. Di Maio M., Chiodini P., Georgoulias V., Hatzidaki D., Takeda K., Wachters F.M., Gebbia V., Smit E.F., Morabito A., Gallo C., Perrone F., Gridelli C. Meta-analysis of single-agent chemotherapy compared with combination chemotherapy as second-line treatment of advanced non-small-cell lung cancer. J. Clin. Oncol. 2009, 27:1836-1843.
101. Chiu G.N., Wong M.Y., Ling L.U., Shaikh I.M., Tan K.B., Chaudhury A., Tan B.J. Lipid-based nanoparticulate systems for the delivery of anti-cancer drug cocktails: implications on pharmacokinetics and drug toxicities. Curr. Drug Metab. 2009, 10:861-874.
102. Shapira A., Livney Y.D., Broxterman H.J., Assaraf Y.G. Nanomedicine for targeted cancer therapy: towards the overcoming of drug resistance. Drug Resist. Updat. 2011, 14:150-163.
103. Yuan H., Li X., Wu J., Li J., Qu X., Xu W., Tang W. Strategies to overcome or circumvent P-glycoprotein mediated multidrug resistance. Curr. Med. Chem. 2008, 15:470-476.
104. Wu J., Lu Y., Lee A., Pan X., Yang X., Zhao X., Lee R.J. Reversal of multidrug resistance by transferrin-conjugated liposomes co-encapsulating doxorubicin and verapamil. J. Pharm. Pharm. Sci. 2007, 10:350-357.
105. Ganta S., Devalapally H., Amiji M. Curcumin enhances oral bioavailability and anti-tumor therapeutic efficacy of paclitaxel upon administration in nanoemulsion formulation. J. Pharm. Sci. 2010, 99:4630-4641.
106. van Vlerken L.E., Duan Z., Seiden M.V., Amiji M.M. Modulation of intracellular ceramide using polymeric nanoparticles to overcome multidrug resistance in cancer. Cancer Res. 2007, 67:4843-4850.
107. Reya T., Morrison S.J., Clarke M.F., Weissman I.L. Stem cells, cancer, and cancer stem cells. Nature 2001, 414:105-111.
108. Deonarain M.P., Kousparou C.A., Epenetos A.A. Antibodies targeting cancer stem cells: a new paradigm in immunotherapy?. MAbs 2009, 1:12-25.
109. Folkins C., Man S., Xu P., Shaked Y., Hicklin D.J., Kerbel R.S. Anticancer therapies combining antiangiogenic and tumor cell cytotoxic effects reduce the tumor stem-like cell fraction in glioma xenograft tumors. Cancer Res. 2007, 67:3560-3564.
110. Kuhnle M., Egger M., Muller C., Mahringer A., Bernhardt G., Fricker G., Konig B., Buschauer A. Potent and selective inhibitors of breast cancer resistance protein (ABCG2) derived from the p-glycoprotein (ABCB1) modulator tariquidar. J. Med. Chem. 2009, 52:1190-1197.
111. Wu C.P., Calcagno A.M., Ambudkar S.V. Reversal of ABC drug transporter-mediated multidrug resistance in cancer cells: evaluation of current strategies. Curr. Mol. Pharmacol. 2008, 1:93-105.
112. Gupta P.B., Onder T.T., Jiang G., Tao K., Kuperwasser C., Weinberg R.A., Lander E.S. Identification of selective inhibitors of cancer stem cells by high-throughput screening. Cell 2009, 138:645-659.
113. Lane A.A., Chabner B.A. Histone deacetylase inhibitors in cancer therapy. J. Clin. Oncol. 2009, 27:5459-5468.
114. Sanz M.A., Martin G., Gonzalez M., Leon A., Rayon C., Rivas C., Colomer D., Amutio E., Capote F.J., Milone G.A., De La Serna J., Roman J., Barragan E., Bergua J., Escoda L., Parody R., Negri S., Calasanz M.J., Bolufer P. Risk-adapted treatment of acute promyelocytic leukemia with all-trans-retinoic acid and anthracycline monochemotherapy: a multicenter study by the PETHEMA group. Blood 2004, 103:1237-1243.
115. Arrieta O., Gonzalez-De la Rosa C.H., Arechaga-Ocampo E., Villanueva-Rodriguez G., Ceron-Lizarraga T.L., Martinez-Barrera L., Vazquez-Manriquez M.E., Rios-Trejo M.A., Alvarez-Avitia M.A., Hernandez-Pedro N., Rojas-Marin C., De la Garza J. Randomized phase II trial of All-trans-retinoic acid with chemotherapy based on paclitaxel and cisplatin as first-line treatment in patients with advanced non-small-cell lung cancer. J. Clin. Oncol. 2010, 28:3463-3471.
116. Liu S., Dontu G., Mantle I.D., Patel S., Ahn N.S., Jackson K.W., Suri P., Wicha M.S. Hedgehog signaling and Bmi-1 regulate self-renewal of normal and malignant human mammary stem cells. Cancer Res. 2006, 66:6063-6071.
117. Bar E.E., Chaudhry A., Lin A., Fan X., Schreck K., Matsui W., Piccirillo S., Vescovi A.L., DiMeco F., Olivi A., Eberhart C.G. Cyclopamine-mediated hedgehog pathway inhibition depletes stem-like cancer cells in glioblastoma. Stem Cells 2007, 25:2524-2533.
118. Feldmann G., Dhara S., Fendrich V., Bedja D., Beaty R., Mullendore M., Karikari C., Alvarez H., Iacobuzio-Donahue C., Jimeno A., Gabrielson K.L., Matsui W., Maitra A. Blockade of hedgehog signaling inhibits pancreatic cancer invasion and metastases: a new paradigm for combination therapy in solid cancers. Cancer Res. 2007, 67:2187-2196.
119. Koch U., Radtke F. Notch and cancer: a double-edged sword. Cell. Mol. Life Sci. 2007, 64:2746-2762.
120. Pannuti A., Foreman K., Rizzo P., Osipo C., Golde T., Osborne B., Miele L. Targeting Notch to target cancer stem cells. Clin. Cancer Res. 2010, 16:3141-3152.
121. Fischer M., Yen W.C., Kapoun A.M., Wang M., O'Young G., Lewicki J., Gurney A., Hoey T. Anti-DLL4 inhibits growth and reduces tumor-initiating cell frequency in colorectal tumors with oncogenic KRAS mutations. Cancer Res. 2011, 71:1520-1525.
122. Moon R.T., Bowerman B., Boutros M., Perrimon N. The promise and perils of Wnt signaling through beta-catenin. Science 2002, 296:1644-1646.
123. Vermeulen L., De Sousa E.M.F., van der Heijden M., Cameron K., de Jong J.H., Borovski T., Tuynman J.B., Todaro M., Merz C., Rodermond H., Sprick M.R., Kemper K., Richel D.J., Stassi G., Medema J.P. Wnt activity defines colon cancer stem cells and is regulated by the microenvironment. Nat. Cell Biol. 2010, 12:468-476.
124. Verma A., Guha S., Diagaradjane P., Kunnumakkara A.B., Sanguino A.M., Lopez-Berestein G., Sood A.K., Aggarwal B.B., Krishnan S., Gelovani J.G., Mehta K. Therapeutic significance of elevated tissue transglutaminase expression in pancreatic cancer. Clin. Cancer Res. 2008, 14:2476-2483.
125. Ganesh S., Iyer A.K., Morrissey D.V., Amiji M.M. Hyaluronic acid based self-assembling nanosystems for CD44 target mediated siRNA delivery to solid tumors. Biomaterials 2013, 34:3489-3502.
126. Ganesh S., Iyer A.K., Weiler J., Morrissey D.V., Amiji M.M. Combination of siRNA directed gene silencing with cisplatin reverses drug resistance in human non-small cell lung cancer. Mol Ther Nucleic Acids 2013, 2:e110.
127. Wang Y., Gao S., Ye W.-H., Yoon H.S., Yang Y.-Y. Co-delivery of drugs and DNA from cationic core-shell nanoparticles self-assembled from a biodegradable copolymer. Nat. Mater. 2006, 5:791-796.
128. Susa M., Iyer A.K., Ryu K., Choy E., Hornicek F.J., Mankin H., Milane L., Amiji M.M., Duan Z. Inhibition of ABCB1 (MDR1) expression by an siRNA nanoparticulate delivery system to overcome drug resistance in osteosarcoma. PLoS One 2010, 5:e10764.
129. Susa M., Iyer A.K., Ryu K., Hornicek F.J., Mankin H., Amiji M.M., Duan Z. Doxorubicin loaded polymeric nanoparticulate delivery system to overcome drug resistance in osteosarcoma. BMC Cancer 2009, 9:399.
130. Saad M., Garbuzenko O.B., Minko T. Co-delivery of siRNA and an anticancer drug for treatment of multidrug-resistant cancer. Nanomedicine (London, England) 2008, 3:761-776.
131. Chen A.M., Zhang M., Wei D., Stueber D., Taratula O., Minko T., He H. Co-delivery of doxorubicin and Bcl-2 siRNA by mesoporous silica nanoparticles enhances the efficacy of chemotherapy in multidrug-resistant cancer cells. Small 2009, 5:2673-2677.
132. Meng H., Mai W.X., Zhang H., Xue M., Xia T., Lin S., Wang X., Zhao Y., Ji Z., Zink J.I., Nel A.E. Codelivery of an optimal drug/siRNA combination using mesoporous silica nanoparticles to overcome drug resistance in breast cancer in vitro and in vivo. ACS Nano 2013, 7:994-1005.
133. Patil Y.B., Swaminathan S.K., Sadhukha T., Ma L., Panyam J. The use of nanoparticle-mediated targeted gene silencing and drug delivery to overcome tumor drug resistance. Biomaterials 2010, 31:358-365.
134. Gillies E.R., Frechet J.M. Dendrimers and dendritic polymers in drug delivery. Drug Discov. Today 2005, 10:35-43.
135. Luo K., Li C., Li L., She W., Wang G., Gu Z. Arginine functionalized peptide dendrimers as potential gene delivery vehicles. Biomaterials 2012, 33:4917-4927.
136. Pandita D., Santos J.L., Rodrigues J., Pego A.P., Granja P.L., Tomas H. Gene delivery into mesenchymal stem cells: a biomimetic approach using RGD nanoclusters based on poly(amidoamine) dendrimers. Biomacromolecules 2011, 12:472-481.
137. Luo K., Li C., Wang G., Nie Y., He B., Wu Y., Gu Z. Peptide dendrimers as efficient and biocompatible gene delivery vectors: synthesis and in vitro characterization. J. Control. Release 2011, 155:77-87.
138. Xu Q., Wang C.H., Pack D.W. Polymeric carriers for gene delivery: chitosan and poly(amidoamine) dendrimers. Curr. Pharm. Des. 2010, 16:2350-2368.
139. Yuan Q., Yeudall W.A., Yang H. PEGylated polyamidoamine dendrimers with bis-aryl hydrazone linkages for enhanced gene delivery. Biomacromolecules 2010, 11:1940-1947.
140. Santos J.L., Pandita D., Rodrigues J., Pego A.P., Granja P.L., Balian G., Tomas H. Receptor-mediated gene delivery using PAMAM dendrimers conjugated with peptides recognized by mesenchymal stem cells. Mol. Pharm. 2010, 7:763-774.
141. Kaneshiro T.L., Lu Z.-R. Targeted intracellular codelivery of chemotherapeutics and nucleic acid with a well-defined dendrimer-based nanoglobular carrier. Biomaterials 2009, 30:5660-5666.
142. Nakamura K., Abu Lila A.S., Matsunaga M., Doi Y., Ishida T., Kiwada H. A double-modulation strategy in cancer treatment with a chemotherapeutic agent and siRNA. Mol. Ther. 2011, 19:2040-2047.
143. Rao D.D., Vorhies J.S., Senzer N., Nemunaitis J. siRNA vs. shRNA: similarities and differences. Adv. Drug Deliv. Rev. 2009, 61:746-759.
144. Kaszubiak A., Holm P.S., Lage H. Overcoming the classical multidrug resistance phenotype by adenoviral delivery of anti-MDR1 short hairpin RNAs and ribozymes. Int. J. Oncol. 2007, 31:419-430.
145. Yin Q., Shen J., Chen L., Zhang Z., Gu W., Li Y. Overcoming multidrug resistance by co-delivery of Mdr-1 and survivin-targeting RNA with reduction-responsible cationic poly(beta-amino esters). Biomaterials 2012, 33:6495-6506.
146. Gerweck L.E., Seetharaman K. Cellular pH gradient in tumor versus normal tissue: potential exploitation for the treatment of cancer. Cancer Res. 1996, 56:1194-1198.
147. Miyata T., Nakamae K., Hoffman A.S., Kanzaki Y. Stimuli-sensitivities of hydrogels containing phosphate groups. Macromol. Chem. Phys. 2003, 195:1111-1120.
148. Lavignac N., Lazenby M., Foka P., Malgesini B., Verpilio I., Ferruti P., Duncan R. Synthesis and endosomolytic properties of poly(amidoamine) block copolymers. Macromol. Biosci. 2004, 4:922-929.
149. Khayat Z., Griffiths P.C., Grillo I., Heenan R.K., King S.M., Duncan R. Characterising the size and shape of polyamidoamines in solution as a function of pH using neutron scattering and pulsed-gradient spin-echo NMR. Int. J. Pharm. 2006, 317:175-186.
150. Richardson S., Ferruti P., Duncan R. Poly(amidoamine)s as potential endosomolytic polymers: evaluation in vitro and body distribution in normal and tumour-bearing animals. J. Drug Target. 1999, 6:391-404.
151. Griffiths P.C., Nilmini R., Carter E., Dodds P., Murphy D.M., Khayat Z., Lattanzio E., Ferruti P., Heenan R.K., King S.M., Duncan R. Interaction of an endosomolytic polyamidoamine ISA23 with vesicles mimicking intracellular membranes: a SANS/EPR study. Macromol. Biosci. 2010, 10:963-973.
152. Griffiths P.C., Khayat Z., Tse S., Heenan R.K., King S.M., Duncan R. Studies on the mechanism of interaction of a bioresponsive endosomolytic polyamidoamine with interfaces. 1. Micelles as model surfaces. Biomacromolecules 2007, 8:1004-1012.
153. Lavignac N., Lazenby M., Franchini J., Ferruti P., Duncan R. Synthesis and preliminary evaluation of poly(amidoamine)-melittin conjugates as endosomolytic polymers and/or potential anticancer therapeutics. Int. J. Pharm. 2005, 300:102-112.
154. Lavignac N., Lazenby M., Foka P., Malgesini B., Verpilio I., Ferruti P., Duncan R. Synthesis and endosomolytic properties of poly(amidoamine) block copolymers. Macromol. Biosci. 2004, 4:922-929.
155. Griffiths P.C., Paul A., Khayat Z., Wan K.W., King S.M., Grillo I., Schweins R., Ferruti P., Franchini J., Duncan R. Understanding the mechanism of action of poly(amidoamine)s as endosomolytic polymers: correlation of physicochemical and biological properties. Biomacromolecules 2004, 5:1422-1427.
156. Griffiths P.C., Mauro N., Murphy D.M., Carter E., Richardson S.C., Dyer P., Ferruti P. Self-assembled PAA-based nanoparticles as potential gene and protein delivery systems. Macromol. Biosci. 2013, 13:641-649.
157. Lavignac N., Nicholls J.L., Ferruti P., Duncan R. Poly(amidoamine) conjugates containing doxorubicin bound via an acid-sensitive linker. Macromol. Biosci. 2009, 9:480-487.
158. Lynn D.M., Amiji M.M., Langer R. pH-responsive polymer microspheres: rapid release of encapsulated material within the range of intracellular pH. Angew. Chem. Int. Ed. Engl. 2001, 40:1707-1710.
159. Shenoy D., Little S., Langer R., Amiji M. Poly(ethylene oxide)-modified poly(beta-amino ester) nanoparticles as a pH-sensitive system for tumor-targeted delivery of hydrophobic drugs. 1. In vitro evaluations. Mol. Pharm. 2005, 2:357-366.
160. Shenoy D., Little S., Langer R., Amiji M. Poly(ethylene oxide)-modified poly(beta-amino ester) nanoparticles as a pH-sensitive system for tumor-targeted delivery of hydrophobic drugs: part 2. In vivo distribution and tumor localization studies. Pharm. Res. 2005, 22:2107-2114.
161. Devalapally H., Shenoy D., Little S., Langer R., Amiji M. Poly(ethylene oxide)-modified poly(beta-amino ester) nanoparticles as a pH-sensitive system for tumor-targeted delivery of hydrophobic drugs: part 3. Therapeutic efficacy and safety studies in ovarian cancer xenograft model. Cancer Chemother. Pharmacol. 2007, 59:477-484.
162. Du J.Z., Du X.J., Mao C.Q., Wang J. Tailor-made dual pH-sensitive polymer-doxorubicin nanoparticles for efficient anticancer drug delivery. J. Am. Chem. Soc. 2011, 133:17560-17563.
163. Obata Y., Tajima S., Takeoka S. Evaluation of pH-responsive liposomes containing amino acid-based zwitterionic lipids for improving intracellular drug delivery in vitro and in vivo. J. Control. Release 2010, 142:267-276.
164. Lee S.M., Chen H., Dettmer C.M., O'Halloran T.V., Nguyen S.T. Polymer-caged liposomes: a pH-responsive delivery system with high stability. J. Am. Chem. Soc. 2007, 129:15096-15097.
165. Yang Q., Wang S., Fan P., Wang L., Di Y., Lin K., Xiao F.-S. pH-responsive carrier system based on carboxylic acid modified mesoporous silica and polyelectrolyte for drug delivery. Chem. Mater. 2005, 17:5999-6003.
166. Park C., Oh K., Lee S.C., Kim C. Controlled release of guest molecules from mesoporous silica particles based on a pH-responsive polypseudorotaxane motif. Angew. Chem. Int. Ed. Engl. 2007, 46:1455-1457.
167. Xue M., Findenegg G.H. Lysozyme as a pH-responsive valve for the controlled release of guest molecules from mesoporous silica. Langmuir 2012, 28:17578-17584.
168. Angelos S., Yang Y.W., Patel K., Stoddart J.F., Zink J.I. pH-responsive supramolecular nanovalves based on cucurbit[6]uril pseudorotaxanes. Angew. Chem. Int. Ed. Engl. 2008, 47:2222-2226.
169. Meng H., Xue M., Xia T., Zhao Y.L., Tamanoi F., Stoddart J.F., Zink J.I., Nel A.E. Autonomous in vitro anticancer drug release from mesoporous silica nanoparticles by pH-sensitive nanovalves. J. Am. Chem. Soc. 2010, 132:12690-12697.
170. He Q., Gao Y., Zhang L., Zhang Z., Gao F., Ji X., Li Y., Shi J. A pH-responsive mesoporous silica nanoparticles-based multi-drug delivery system for overcoming multi-drug resistance. Biomaterials 2011, 32:7711-7720.
171. Saito G., Swanson J.A., Lee K.D. Drug delivery strategy utilizing conjugation via reversible disulfide linkages: role and site of cellular reducing activities. Advanced Drug Delivery Reviews 2003, 55:199-215.
172. Schafer F.Q., Buettner G.R. Redox environment of the cell as viewed through the redox state of the glutathione disulfide/glutathione couple. Free Radic. Biol. Med. 2001, 30:1191-1212.
173. Arunachalam B., Phan U.T., Geuze H.J., Cresswell P. Enzymatic reduction of disulfide bonds in lysosomes: characterization of a gamma-interferon-inducible lysosomal thiol reductase (GILT). Proc. Natl. Acad. Sci. U.S.A. 2000, 97:745-750.
174. Cavallaro G., Campisi M., Licciardi M., Ogris M., Giammona G. Reversibly stable thiopolyplexes for intracellular delivery of genes. J. Control. Release 2006, 115:322-334.
175. Kommareddy S., Amiji M. Preparation and evaluation of thiol-modified gelatin nanoparticles for intracellular DNA delivery in response to glutathione. Bioconjug. Chem. 2005, 16:1423-1432.
176. Kommareddy S., Amiji M. Poly(ethylene glycol)-modified thiolated gelatin nanoparticles for glutathione-responsive intracellular DNA delivery. Nanomedicine 2007, 3:32-42.
177. Kommareddy S., Amiji M. Biodistribution and pharmacokinetic analysis of long-circulating thiolated gelatin nanoparticles following systemic administration in breast cancer-bearing mice. J. Pharm. Sci. 2007, 96:397-407.
178. Kommareddy S., Amiji M. Antiangiogenic gene therapy with systemically administered sFlt-1 plasmid DNA in engineered gelatin-based nanovectors. Cancer Gene Ther. 2007, 14:488-498.
179. Gabizon A.A., Tzemach D., Horowitz A.T., Shmeeda H., Yeh J., Zalipsky S. Reduced toxicity and superior therapeutic activity of a mitomycin C lipid-based prodrug incorporated in pegylated liposomes. Clin. Cancer Res 2006, 12:1913-1920.
180. Lutz J.-F., Hoth A. Preparation of ideal PEG analogues with a tunable thermosensitivity by controlled radical copolymerization of 2-(2-methoxyethoxy) ethyl methacrylate and oligo (ethylene glycol) methacrylate. Macromolecules 2006, 39:893-896.
181. Lutz J.-F. Polymerization of oligo (ethylene glycol)(meth) acrylates: toward new generations of smart biocompatible materials. J. Polym. Sci. A 2008, 46:3459-3470.
182. Ward M.A., Georgiou T.K. Thermoresponsive terpolymers based on methacrylate monomers: effect of architecture and composition. J. Polym. Sci. A 2010, 48:775-783.
183. Meewes M., Ricka J., De Silva M., Nyffenegger R., Binkert T. Coil-globule transition of poly (N-isopropylacrylamide): a study of surfactant effects by light scattering. Macromolecules 1991, 24:5811-5816.
184. Doorty K.B., Golubeva T.A., Gorelov A.V., Rochev Y.A., Allen L.T., Dawson K.A., Gallagher W.M., Keenan A.K. Poly(N-isopropylacrylamide) co-polymer films as potential vehicles for delivery of an antimitotic agent to vascular smooth muscle cells. Cardiovasc. Pathol. 2003, 12:105-110.
185. Hacker M.C., Klouda L., Ma B.B., Kretlow J.D., Mikos A.G. Synthesis and characterization of injectable, thermally and chemically gelable, amphiphilic poly(N-isopropylacrylamide)-based macromers. Biomacromolecules 2008, 9:1558-1570.
186. Yin X., Hoffman A.S., Stayton P.S. Poly(N-isopropylacrylamide-co-propylacrylic acid) copolymers that respond sharply to temperature and pH. Biomacromolecules 2006, 7:1381-1385.
187. Li Y., Pan S., Zhang W., Du Z. Novel thermo-sensitive core-shell nanoparticles for targeted paclitaxel delivery. Nanotechnology 2009, 20:065104.
188. Vihola H., Laukkanen A., Tenhu H., Hirvonen J. Drug release characteristics of physically cross-linked thermosensitive poly(N-vinylcaprolactam) hydrogel particles. J. Pharm. Sci. 2008, 97:4783-4793.
189. Kurisawa M., Yokoyama M., Okano T. Gene expression control by temperature with thermo-responsive polymeric gene carriers. J. Control. Release 2000, 69:127-137.
190. Wang Q., Li S., Wang Z., Liu H., Li C. Preparation and characterization of a positive thermoresponsive hydrogel for drug loading and release. J. Appl. Polym. Sci. 2008, 111:1417-1425.
191. Loh X.J., Zhang Z.-X., Wu Y.-L., Lee T.S., Li J. Synthesis of novel biodegradable thermoresponsive triblock copolymers based on poly [(R)-3-hydroxybutyrate] and poly (N-isopropylacrylamide) and their formation of thermoresponsive micelles. Macromolecules 2008, 42:194-202.
192. Read E.S., Armes S.P. Recent advances in shell cross-linked micelles. Chem. Commun. (Camb) 2007, 3021-3035.
193. Meng F., Zhong Z., Feijen J. Stimuli-responsive polymersomes for programmed drug delivery. Biomacromolecules 2009, 10:197-209.
194. Ward M.A., Georgiou T.K. Thermoresponsive polymers for biomedical applications. Polymers 2011, 3:1215-1242.
195. Demel R.A., De Kruyff B. The function of sterols in membranes. Biochim. Biophys. Acta 1976, 457:109-132.
196. Anyarambhatla G.R., Needham D. Enhancement of the phase transition permeability of DPPC liposomes by incorporation of MPPC: a new temperature-sensitive liposome for use with mild hyperthermia. J. Liposome. Res. 1999, 9:491-506.
197. Kong G., Anyarambhatla G., Petros W.P., Braun R.D., Colvin O.M., Needham D., Dewhirst M.W. Efficacy of liposomes and hyperthermia in a human tumor xenograft model: importance of triggered drug release. Cancer Res. 2000, 60:6950-6957.
198. Manzoor A.A., Lindner L.H., Landon C.D., Park J.Y., Simnick A.J., Dreher M.R., Das S., Hanna G., Park W., Chilkoti A., Koning G.A., ten Hagen T.L., Needham D., Dewhirst M.W. Overcoming limitations in nanoparticle drug delivery: triggered, intravascular release to improve drug penetration into tumors. Cancer Res. 2012, 72:5566-5575.
199. Paasonen L., Romberg B., Storm G., Yliperttula M., Urtti A., Hennink W.E. Temperature-sensitive poly(N-(2-hydroxypropyl)methacrylamide mono/dilactate)-coated liposomes for triggered contents release. Bioconjug. Chem. 2007, 18:2131-2136.
200. Yoshino K., Kadowaki A., Takagishi T., Kono K. Temperature sensitization of liposomes by use of N-isopropylacrylamide copolymers with varying transition endotherms. Bioconjug. Chem. 2004, 15:1102-1109.
201. Kono K., Ozawa T., Yoshida T., Ozaki F., Ishizaka Y., Maruyama K., Kojima C., Harada A., Aoshima S. Highly temperature-sensitive liposomes based on a thermosensitive block copolymer for tumor-specific chemotherapy. Biomaterials 2010, 31:7096-7105.
202. Kono K., Nakashima S., Kokuryo D., Aoki I., Shimomoto H., Aoshima S., Maruyama K., Yuba E., Kojima C., Harada A., Ishizaka Y. Multi-functional liposomes having temperature-triggered release and magnetic resonance imaging for tumor-specific chemotherapy. Biomaterials 2011, 32:1387-1395.
203. Kono K., Takagishi T. Temperature-sensitive liposomes. Methods Enzymol. 2004, 387:73-82.
204. Li L., ten Hagen T.L., Schipper D., Wijnberg T.M., van Rhoon G.C., Eggermont A.M., Lindner L.H., Koning G.A. Triggered content release from optimized stealth thermosensitive liposomes using mild hyperthermia. J. Control. Release 2010, 143:274-279.
205. Huang S.K., Stauffer P.R., Hong K., Guo J.W., Phillips T.L., Huang A., Papahadjopoulos D. Liposomes and hyperthermia in mice: increased tumor uptake and therapeutic efficacy of doxorubicin in sterically stabilized liposomes. Cancer Res. 1994, 54:2186-2191.
206. Dromi S., Frenkel V., Luk A., Traughber B., Angstadt M., Bur M., Poff J., Xie J., Libutti S.K., Li K.C., Wood B.J. Pulsed-high intensity focused ultrasound and low temperature-sensitive liposomes for enhanced targeted drug delivery and antitumor effect. Clin. Cancer Res. 2007, 13:2722-2727.
207. Purushotham S., Chang P.E., Rumpel H., Kee I.H., Ng R.T., Chow P.K., Tan C.K., Ramanujan R.V. Thermoresponsive core-shell magnetic nanoparticles for combined modalities of cancer therapy. Nanotechnology 2009, 20:305101.
208. Cheung A.Y., Neyzari A. Deep local hyperthermia for cancer therapy: external electromagnetic and ultrasound techniques. Cancer Res. 1984, 44:4736s-4744s.
209. Li L., ten Hagen T.L., Bolkestein M., Gasselhuber A., Yatvin J., van Rhoon G.C., Eggermont A.M., Haemmerich D., Koning G.A. Improved intratumoral nanoparticle extravasation and penetration by mild hyperthermia. J. Control. Release 2013, 167:130-137.
210. Chung C.-M., Roh Y.-S., Cho S.-Y., Kim J.-G. Crack healing in polymeric materials via photochemical [2+2] cycloaddition. Chem. Mater. 2004, 16:3982-3984.
211. Lendlein A., Jiang H., Jünger O., Langer R. Light-induced shape-memory polymers. Nature 2005, 434:879-882.
212. Sumaru K., Ohi K., Takagi T., Kanamori T., Shinbo T. Photoresponsive properties of poly (N-isopropylacrylamide) hydrogel partly modified with spirobenzopyran. Langmuir 2006, 22:4353-4356.
213. Chen Z., He Y., Wang Y., Wang X. Amphiphilic diblock copolymer with dithienylethene pendants: synthesis and photo-modulated self-assembly. Macromol. Rapid Commun. 2011, 32:977-982.
214. Jiang J., Qi B., Lepage M., Zhao Y. Polymer micelles stabilization on demand through reversible photo-cross-linking. Macromolecules 2007, 40:790-792.
215. Katz J.S., Zhong S., Ricart B.G., Pochan D.J., Hammer D.A., Burdick J.A. Modular synthesis of biodegradable diblock copolymers for designing functional polymersomes. J. Am. Chem. Soc. 2010, 132:3654-3655.
216. Han D., Tong X., Zhao Y. Fast photodegradable block copolymer micelles for burst release. Macromolecules 2011, 44:437.
217. Jiang J., Tong X., Zhao Y. A new design for light-breakable polymer micelles. J. Am. Chem. Soc. 2005, 127:8290-8291.
218. Jiang J., Tong X., Morris D., Zhao Y. Toward photocontrolled release using light-dissociable block copolymer micelles. Macromolecules 2006, 39:4633.
219. Haase M., Schafer H. Upconverting nanoparticles. Angew. Chem. Int. Ed. Engl. 2011, 50:5808-5829.
220. Yan B., Boyer J.C., Branda N.R., Zhao Y. Near-infrared light-triggered dissociation of block copolymer micelles using upconverting nanoparticles. J. Am. Chem. Soc. 2011, 133:19714-19717.
221. Yavlovich A., Singh A., Blumenthal R., Puri A. A novel class of photo-triggerable liposomes containing DPPC:DC(8,9)PC as vehicles for delivery of doxorubcin to cells. Biochim. Biophys. Acta 2011, 1808:117-126.
222. Alvarez-Lorenzo C., Bromberg L., Concheiro A. Light-sensitive intelligent drug delivery systems. Photochem. Photobiol. 2009, 85:848-860.
223. Husseini G.A., Myrup G.D., Pitt W.G., Christensen D.A., Rapoport N.Y. Factors affecting acoustically triggered release of drugs from polymeric micelles. J. Control. Release 2000, 69:43-52.
224. Husseini G.A., Pitt W.G., Christensen D.A., Dickinson D.J. Degradation kinetics of stabilized pluronic micelles under the action of ultrasound. J. Control. Release 2009, 138:45-48.
225. Hernot S., Klibanov A.L. Microbubbles in ultrasound-triggered drug and gene delivery. Adv. Drug Deliv. Rev. 2008, 60:1153-1166.
226. Chen S., Ding J.H., Bekeredjian R., Yang B.Z., Shohet R.V., Johnston S.A., Hohmeier H.E., Newgard C.B., Grayburn P.A. Efficient gene delivery to pancreatic islets with ultrasonic microbubble destruction technology. Proc. Natl. Acad. Sci. U.S.A. 2006, 103:8469-8474.
227. Kheirolomoom A., Dayton P.A., Lum A.F., Little E., Paoli E.E., Zheng H., Ferrara K.W. Acoustically-active microbubbles conjugated to liposomes: characterization of a proposed drug delivery vehicle. J. Control. Release 2007, 118:275-284.
228. Marin A., Muniruzzaman M., Rapoport N. Acoustic activation of drug delivery from polymeric micelles: effect of pulsed ultrasound. J. control. Release 2001, 71:239-249.
229. Husseini G.A., Christensen D.A., Rapoport N.Y., Pitt W.G. Ultrasonic release of doxorubicin from Pluronic P105 micelles stabilized with an interpenetrating network of N,N-diethylacrylamide. J. Control. Release 2002, 83:303-305.
230. Marin A., Sun H., Husseini G.A., Pitt W.G., Christensen D.A., Rapoport N.Y. Drug delivery in pluronic micelles: effect of high-frequency ultrasound on drug release from micelles and intracellular uptake. J. Control. Release 2002, 84:39-47.
231. Rapoport N., Marin A., Luo Y., Prestwich G.D., Muniruzzaman M.D. Intracellular uptake and trafficking of Pluronic micelles in drug-sensitive and MDR cells: effect on the intracellular drug localization. J. Pharm. Sci. 2002, 91:157-170.
232. Gao Z., Fain H.D., Rapoport N. Ultrasound-enhanced tumor targeting of polymeric micellar drug carriers. Mol. Pharm. 2004, 1:317-330.
233. Gao Z.G., Fain H.D., Rapoport N. Controlled and targeted tumor chemotherapy by micellar-encapsulated drug and ultrasound. J. Control. Release 2005, 102:203-222.
234. Hua M.Y., Yang H.W., Chuang C.K., Tsai R.Y., Chen W.J., Chuang K.L., Chang Y.H., Chuang H.C., Pang S.T. Magnetic-nanoparticle-modified paclitaxel for targeted therapy for prostate cancer. Biomaterials 2010, 31:7355-7363.
235. Brazel C.S. Magnetothermally-responsive nanomaterials: combining magnetic nanostructures and thermally-sensitive polymers for triggered drug release. Pharm. Res. 2009, 26:644-656.
236. Hu S.-H., Liu T.-Y., Liu D.-M., Chen S.-Y. Controlled pulsatile drug release from a ferrogel by a high-frequency magnetic field. Macromolecules 2007, 40:6786-6788.
237. Hu S.-H., Chen S.-Y., Liu D.-M., Hsiao C.-S. Core/single-crystal-shell nanospheres for controlled drug release via a magnetically triggered rupturing mechanism. Adv. Mater. 2008, 20:2690-2695.
238. Oliveira H., Perez-Andres E., Thevenot J., Sandre O., Berra E., Lecommandoux S. Magnetic field triggered drug release from polymersomes for cancer therapeutics. J. Control. Release 2013, 169:165-170.
239. Svirskis D., Travas-Sejdic J., Rodgers A., Garg S. Electrochemically controlled drug delivery based on intrinsically conducting polymers. J. Control. Release 2010, 146:6-15.
240. George P.M., LaVan D.A., Burdick J.A., Chen C.Ä., Liang E., Langer R. Electrically controlled drug delivery from biotin-doped conductive polypyrrole. Adv. Mater. 2006, 18:577-581.
241. Wadhwa R., Lagenaur C.F., Cui X.T. Electrochemically controlled release of dexamethasone from conducting polymer polypyrrole coated electrode. J. Control. Release 2006, 110:531-541.
242. Ge J., Neofytou E., Cahill T.J., Beygui R.E., Zare R.N. Drug release from electric-field-responsive nanoparticles. ACS Nano 2012, 6:227-233.